Sionna Therapeutics reports early-stage cystic fibrosis trial failure, dampening challenge to Vertex

Sionna Therapeutics said its lead cystic fibrosis drug did not meet primary endpoints in an early-stage study, marking a setback for the company.

The result reduces expectations that Sionna could soon rival Vertex Pharmaceuticals, which dominates the cystic fibrosis market.

Analysts note the failure may prompt the company to revisit its development strategy and could weigh on its stock as investors reassess the pipeline.